01 June 2016
Washington DC
Reporter: Tammy Facey

Microsoft transfers patents to Xiaomi


Microsoft has agreed to transfer patents to electronics company Xiaomi in a deal that will see Office and Skype installed on its Android devices.

Under the agreement, Xiaomi’s Android products will employ Microsoft Office and Skype video-calling. The deal includes a cross-licence and the transfer of unnamed patents to the China-based company.

Further details were not disclosed.

In September, Xiaomi’s mobile devices, including the Mi 5, Mi Max and Redmi 3, will come pre-installed with Microsoft Office software, including Word, Excel, PowerPoint and Outlook, as well as Skype.

As a result of the collaboration, Xiaomi said in a statement, customers in China, India and around the world “will have new ways to work, collaborate and communicate.”

Xiang Wang, senior vice president at Xiaomi, said: “As demonstrated by this agreement with Microsoft, Xiaomi is looking to build sustainable, long-term partnerships with global technology leaders, with the ultimate goal of bringing the best user experience to our Mi fans.”

“People want their favourite apps and experiences to work seamlessly on the device of their choice, and that’s exactly what this partnership offers,” added Peggy Johnson, executive vice president of business development at Microsoft.

“Together with Xiaomi, we’re bringing the very best in mobile productivity to millions more customers in China and around the world.”

Microsoft is expanding its reach in Asia. Last week, the company signed a patent deal with Japan-based accessory manufacturer ELECOM.

The company has entered into more than 1,200 licensing agreements since the launch of its programme in December 2003, which reportedly brings in more than $3 billion in licensing fees per year.

Tristan Sherliker, associate solicitor at law firm EIP, said Xiaomi’s business focus is almost entirely on markets in the likes of China and Malaysia, but its agreement with Microsoft could help it reach other markets.

“This new patent pot from Microsoft might just be what Xiaomi needs to break in to the wider global market: now that it owns patented tech, as well as using it in its smartphones, Xiaomi is in a much better position to compete with rivals such as Apple and Samsung.”

More Asia news
The latest news from IPPro Patents
Join Our Newsletter

Sign up today and never
miss the latest news or an issue again

Subscribe now
Qualcomm hit with $775 million fine in Taiwan
13 October 2017 | Taipei | Reporter: Barney Dixon
Qualcomm has been hit with a $775 million fine, after the Taiwan Fair Trade Commission found that the chipmaker had abused its position in the baseband chip market
Chinese patent examiners need stronger legal sense
15 September 2017 | London | Reporter: Barney Dixon
Chinese patent examiner’s need their legal sense to be strengthened if they are to have an accurate grasp of the provisions of Chinese patent law, according to Owen Ma, manager of the patent application department at China Patent Agent
Qualcomm loses KFTC appeal
05 September 2017 | Seoul | Reporter: Barney Dixon
The semiconductor company lost a bid to overturn an order forcing it to engage in ‘good-faith negotiations’ with chip companies
AIPPI Sydney is coming
01 September 2017 | Sydney | Reporter: Barney Dixon
A busy year at the AIPPI will culminate in a world congress in Sydney in October
Australian government to abolish innovation patent
29 August 2017 | Canberra | Reporter: Barney Dixon
The innovation system is unlikely to provide net benefits to the Australian community or to small- and medium-sized enterprises
Trump fires forward in China IP investigation
15 August 2017 | Washington DC | Reporter: Barney Dixon
US President Donald Trump has signed a memorandum asking the US Trade Representative to examine whether China should be investigated for alleged intellectual property malpractice
SIPO launches new IP rights centre
03 August 2017 | Shanghai | Reporter: Barney Dixon
The centre will focus on providing fast protection for rights in the manufacturing and biopharmaceutical industries